Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Celularity Inc.NASDAQ: CELU

Gross Margin · Q4 FY2025 · quarter ended Dec 2025

Gross margin widens to 208.5%

Gross margin was 208.5% in Q4 FY2025, up 149.0 pp from a year earlier. On a trailing-twelve-month basis it was 76.0%, up 3.7 pp year over year. Over 3 fiscal years it widened by 85.4 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
208.5%+146.7 pp QoQ
Last fiscal yearDec 2025
76.0%+3.7 pp YoY
LTMDec 2025
76.0%+3.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+149.0 pp——
1 year+3.7 pp——
3 years+85.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
76.0%
Year-over-year change
+3.7pp

Gross Margin vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's LTM Dec 2025 gross margin of 76.0% is the lowest of the 2 companies compared; the peer median is 101.1%.
  • Over three fiscal years its change of +85.4 pp compares with a peer median of +0.0 pp.
CELU Competitors Peer median
Gross Margin for CELU and competitors
Company Period LTM level YoY 3-year change
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026101.1% —+0.0 pp
CELUCelularity Inc.LTM Dec 202576.0% +3.7 pp+85.4 pp
PYPDPolyPid Ltd.FY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
Peer median (excluding CELU) 101.1%—+0.0 pp

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.34M17.98M22.77M54.22M26.55M
Cost of Revenue9.65M19.67M16.02M14.99M6.36M
Gross Profit11.68M(1.69M)6.76M39.23M20.19M
Gross Margin54.8%-9.4%29.7%72.4%76.0%
Research & Development88.35M78.36M30.47M17.39M15.03M
Selling, General & Admin71.34M66.02M50.58M58.64M51.27M
Operating Expenses120.74M23.91M199.04M77.59M81.5M
Depreciation & Amortization8.82M9.44M9.32M7.92M7.3M
EBITDA(88.11M)(138.83M)(183.95M)(43.71M)(77.66M)
EBITDA Margin-413.0%-772.4%-807.8%-80.6%-292.5%
Operating Income(109.06M)(25.6M)(192.29M)(38.36M)(61.31M)
Operating Margin-511.2%-142.4%-844.4%-70.7%-230.9%
Interest Income332K365K320K331K262K
Interest Expense3.17M03.02M6.26M6.75M
Other Income / Expenses8.96M39.81M(4M)(19.53M)(30.41M)
Income Before Tax(100.1M)14.21M(196.29M)(57.89M)(91.71M)
Pre-Tax Margin-469.2%79.0%-862.0%-106.8%-345.4%
Income Tax Expense20K13K10K03K
Net Income(100.12M)14.19M(196.3M)(57.89M)(91.8M)
Net Margin-469.3%79.0%-862.0%-106.8%-345.8%
EPS (Basic)(7.87)1.01(11.02)(2.64)(3.59)
EPS (Diluted)(7.87)0.95(11.02)(2.64)(3.59)
Weighted Avg Shares12.73M13.99M17.81M21.89M25.6M
Weighted Avg Shares (Diluted)12.73M14.98M17.81M21.89M25.6M

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.